Goji Berry Fruit Extract Suppresses Cell Proliferation of Breast Cancer Cells by Inhibiting EGFR/ERK Signalling

Herbal medicines have been used in cancer treatment, with many exhibiting favorable side effect and toxicity profiles compared with conventional chemotherapeutic agents. The aim of this study was to verify whether Lycium barbarum fruit (red and black fruit) extracts inhibit proliferation of MDA-MB-2...

Full description

Saved in:
Bibliographic Details
Published inProceedings Vol. 1; no. 10; p. 1058
Main Authors Hatice Bekci, Guzide Satır Basaran, Ayse Baldemir, Ahmet Cumaoglu
Format Journal Article
LanguageEnglish
Published MDPI AG 01.11.2017
Subjects
cancer
EGFR/ERK
Goji berry
Online AccessGet full text

Cover

More Information
Summary:Herbal medicines have been used in cancer treatment, with many exhibiting favorable side effect and toxicity profiles compared with conventional chemotherapeutic agents. The aim of this study was to verify whether Lycium barbarum fruit (red and black fruit) extracts inhibit proliferation of MDA-MB-231cells through EGFR/ERK pathway. Cytotoxicity with MTT reduction assay and phosphorylation of EGFR and ERK were analyzed by western blot. IC50 values were 87.0 and 79.4 µg/mL for goji berry black fruit extract (GBBFE) and goji berry red fruit extract (GBRFE) expectively. Pretreatment with both extract inhibited phosphorylation of EGFR/ERK in EGF-treated cells. Goji berry fruit extracts cause cellular death of MDA-MB-231 breast cancer cells by inhibiting EGFR/ERK signaling and this study suggests that Goji berry fruit extracts could be beneficial for treating breast cancer.
ISSN:2504-3900
DOI:10.3390/proceedings1101058